Drugs / PTC13
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06821048 | Jul 2024 → Jun 2026 overdue | colorectal cancer, gastric cancer, malignant pancreatic neoplasm, metastatic malignant neoplasm | Weijia Fang, MD | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PTC13 | “FAST targeted chimeric antigen receptor (CAR)-T cells (PTC13)” NCT06821048 ↗ |
| Known as | FAST CAR-T | “to obtain the maximum tolerated dose of FAST CAR-T (PTC13) and phase II Recommended dose.” NCT06821048 ↗ |
| Modality | Cell therapy | “FAST targeted chimeric antigen receptor (CAR)-T cells (PTC13)” NCT06821048 ↗ |
| Route | Other | “one intraperitoneal infusion group only” NCT06821048 ↗ |